KLHL18

Across TCGA pan-cancer cohorts, KLHL18 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of KLHL18’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where KLHL18 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types KLHL18 is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

LIHC, KIRC, and COAD are the cancer types where KLHL18 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KLHL18 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+0.673	<.001	9	view →
KIRC	Male	II,III,IV	−0.590	<.001	9	view →
COAD	Female	All	+0.505	<.001	9	view →
UCEC	All	III,IV	+0.947	.002	6	view →
CHOL	Male	All	+1.596	<.001	5	view →
KICH	All	All	−0.674	<.001	5	view →
STAD	All	II,III,IV	+0.588	.003	4	view →
LUSC	All	All	−0.264	<.001	4	view →
BRCA	All	All	+0.224	<.001	4	view →
READ	All	III,IV	+0.820	.005	2	view →
BLCA	Male	III,IV	+0.342	.029	1	view →
THCA	All	II,III,IV	−0.267	.033	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

KLHL18–LIHC

Open the LIHC breakdown →